IRWD Share Price

Open 15.70 Change Price %
High 15.85 1 Day -0.39 -2.50
Low 15.15 1 Week -1.41 -8.48
Close 15.21 1 Month 2.55 20.14
Volume 1135906 1 Year 3.13 25.91
52 Week High 16.89
52 Week Low 0.00
IRWD Important Levels
Resistance 2 15.86
Resistance 1 15.59
Pivot 15.40
Support 1 14.83
Support 2 14.56
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
FB 115.10 -2.80%
MU 18.48 -5.38%
MU 18.48 -5.38%
More..
NASDAQ USA Top Gainers Stocks
LIWA 0.02 100.00%
VALV 0.06 100.00%
LOCM 0.09 50.00%
APPY 4.40 46.67%
TWER 0.30 36.36%
MEMP 0.70 34.62%
MYRX 0.04 33.33%
SCHS 0.12 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
AMCF 0.06 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
RITT 0.06 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)

IRWD Technical Analysis 4
As on 1st Dec 2016 IRWD Share Price closed @ 15.21 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 12.41 & Buy for SHORT-TERM with Stoploss of 15.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
IRWD Target for December
1st Target up-side 18.01
2nd Target up-side 19.7
3rd Target up-side 21.38
1st Target down-side 13.21
2nd Target down-side 11.52
3rd Target down-side 9.84
IRWD Other Details
Segment EQ
Market Capital 1211006720.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ironwoodpharma.com
IRWD Address
IRWD
301 Binney Street
Cambridge, MA 02142
United States
Phone: 617-621-7722
Fax: 617-494-0480
IRWD Latest News
Interactive Technical Analysis Chart Ironwood Pharmaceuticals, Inc. ( IRWD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ironwood Pharmaceuticals, Inc.
IRWD Business Profile
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines. The Company is engaged in the area of guanylate cyclase type-C (GC-C), agonists and in the science and treatment of gastrointestinal diseases. Its two GC-C agonists are linaclotide and IW-9179.